Roche Proteomics Group Focusing On Ways To Diagnosis Alzheimer's Disease
Executive Summary
Measuring protein differences for the diagnosis and treatment of Alzheimer's disease is among the projects currently being pursued by Roche's proteomics group.
You may also be interested in...
Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.
Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.
Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.
Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.
Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do
Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: